Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function

por Ott, Patrick A., Bhardwaj, Nina
Publicado 2013

Advances in the development of personalized neoantigen-based therapeutic cancer vaccines

por Blass, Eryn, Ott, Patrick A.
Publicado 2021

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy

por Luke, Jason J, Ott, Patrick A
Publicado 2014

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma

por Luke, Jason J., Ott, Patrick A.
Publicado 2015

PD-1 inhibitors in endometrial cancer

por Barroso-Sousa, Romualdo, Ott, Patrick A.
Publicado 2017

Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era

por Lamba, Nayan, Ott, Patrick A., Iorgulescu, J. Bryan
Publicado 2022

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial...

por Ott, Patrick A., Hodi, F. Stephen, Buchbinder, Elizabeth I.
Publicado 2015

Combination immunotherapy: a road map

por Ott, Patrick A., Hodi, F. Stephen, Kaufman, Howard L., Wigginton, Jon M., Wolchok, Jedd D.
Publicado 2017

Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab

por Moreira, Raphael B., Hamieh, Lana, Gjini, Evisa, Lako, Ana, Krajewski, Katherine M., Yoon, Charles H., Ott, Patrick A.
Publicado 2017

Topical imiquimod and cryotherapy in combination with systemic immunotherapy in unresectable stage IIIC melanoma

por Yeh, Jennifer E., Wan, Marilyn T., Alloo, Allireza, Ibrahim, Nageatte, Ott, Patrick A., Buchbinder, Elizabeth I., Lin, Jennifer Y.
Publicado 2022

Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma

por Marmarelis, Melina E., Davis, Meredith R., Sethi, Nilay S., Krajewksi, Katherine M., McKay, Rana R., Choueiri, Toni K., Ott, Patrick A.
Publicado 2016

Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition

por Naik, Girish S., Waikar, Sushrut S., Johnson, Alistair E. W., Buchbinder, Elizabeth I., Haq, Rizwan, Hodi, F. Stephen, Schoenfeld, Jonathan D., Ott, Patrick A.
Publicado 2019

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series

por Martini, Dylan J., Lalani, Aly-Khan A., Bossé, Dominick, Steinharter, John A., Harshman, Lauren C., Hodi, F. Stephen, Ott, Patrick A., Choueiri, Toni K.
Publicado 2017

Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy

por Buchbinder, Elizabeth I., Pfaff, Kathleen L., Turner, Madison M., Manos, Michael, Ouyang, Olivia, Ott, Patrick A., Giobbie-Hurder, Anita, Rodig, Scott J., Hodi, F. Stephen
Publicado 2023

Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy

por Dunlap, Garrett S., DiToro, Daniel, Henderson, Joel, Shah, Sujal I., Manos, Mike, Severgnini, Mariano, Weins, Astrid, Guleria, Indira, Ott, Patrick A., Murakami, Naoka, Rao, Deepak A.
Publicado 2023

Topical imiquimod in combination with brachytherapy for unresectable cutaneous melanoma scalp metastases

por Yeh, Jennifer E., Wan, Marilyn T., Alloo, Allireza, Ibrahim, Nageatte, Buzurovic, Ivan, Cohen, Jeffrey M., Ott, Patrick A., Laga, Alvaro C., Devlin, Phillip M., Lin, Jennifer Y.
Publicado 2022

A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma

por Ott, Patrick A., Hamilton, Anne, Jones, Amanda, Haas, Naomi, Shore, Tsiporah, Liddell, Sandra, Christos, Paul J., Doyle, L. Austin, Millward, Michael, Muggia, Franco M., Pavlick, Anna C.
Publicado 2010

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in pat...

por Weber, Jeffrey, Grob, Jean-Jaques, Margolin, Kim A, Ascierto, Paolo A, Sznol, Mario, Ott, Patrick A, Lejeune, Chantal, de Pril, Veerle, Ruisi, Mary M, Hodi, F Stephen
Publicado 2015

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

por Heinzerling, Lucie, Ott, Patrick A., Hodi, F. Stephen, Husain, Aliya N., Tajmir-Riahi, Azadeh, Tawbi, Hussein, Pauschinger, Matthias, Gajewski, Thomas F., Lipson, Evan J., Luke, Jason J.
Publicado 2016

Correction to: Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer

por Chau, Ian, Le, Dung T., Ott, Patrick A., Korytowsky, Beata, Le, Hannah, Le, T. Kim, Zhang, Ying, Sanchez, Teresa, Maglinte, Gregory A., Laurie, Melissa, Abraham, Pranav, Patel, Dhiren, Shangguan, Tong
Publicado 2019